Falling out of HIV care — what really pushes people out, and how to come back.

There is a version of the HIV care story that gets told at conferences: you test, you link, you start treatment, you become undetectable, you stay that way for fifty years. It is a good story. It is also not what happens to most people.

What actually happens is that a job ends and insurance goes with it. A lease falls through. A parent gets sick in another state. A refill sits at a pharmacy with no bus that goes there. An appointment is offered at 9 a.m. on a Tuesday by an employer who does not give sick time. Someone says something cruel in a waiting room and going back stops feeling safe. Six months pass. Then a year. And then the gap itself becomes the reason not to return, because now there would be something to explain.

Notice what that list has in common: almost none of it is a decision. This page is about the gap — what creates it, what happens in your body while it lasts, and exactly how people come back. The headline is simpler than the data: you can come back, and the people who run HIV clinics want you to.

Start here: people are pushed out, they do not simply fall

People do not simply "fall" out of HIV care. Something does the pushing. Insurance vanishes when a job ends. Rent climbs and housing goes unstable. No bus route reaches the clinic. Immigration status turns every intake form into a risk calculation. Drug use is criminalized instead of treated. Medical racism makes being believed harder. A mental health crisis arrives and the next available appointment is eleven weeks out. A work schedule does not bend. And underneath all of it sits the ordinary emotional weight of managing a lifelong diagnosis in a country that still treats it as a moral verdict.

Public health has a name for those forces. Social determinants of health are, in the federal government's own definition, "the conditions in the environments where people are born, live, learn, work, play, worship, and age that affect a wide range of health, functioning, and quality-of-life outcomes and risks" — grouped by Healthy People 2030 into economic stability, education access and quality, health care access and quality, neighborhood and built environment, and social and community context. CDC applies that framework directly to HIV. Its surveillance report on social determinants among adults diagnosed in 2023 tracks federal poverty status, median household income, education level, health insurance coverage, cost-burdened households, and residential instability — and finds the least favorable outcomes, meaning the highest diagnosis rates, the lowest linkage to care within a month, and the lowest viral suppression within six months, concentrated in the counties facing the greatest economic and social challenges.23

Even the phrase "falling out of care" can carry blame it has not earned. This page uses it because that is the label CDC and HRSA attach to the data and the programs, but the accurate sentence runs the other direction: a fragmented, expensive, often stigmatizing system pushes people out — and most of them were doing their best inside it the entire time. Everything below is written from that starting point. None of it is a lecture, and none of it asks you to account for yourself.

The scale confirms it. At the end of 2024, an estimated 1,103,895 people aged 13 and older were living with diagnosed HIV in the United States. Of that group, 77.0% received any HIV medical care during the year — and only 56% met the federal definition of retention in care, meaning two or more HIV care visits, tests, or documented encounters at least three months apart.1

Read that again, because it reframes everything: more than four in ten people living with diagnosed HIV in this country were not in continuous care in 2024. Not a fringe. Close to half.

The pattern holds at the individual level too. In the CDC's Medical Monitoring Project, which interviews people living with HIV and reviews their medical records, 83% were prescribed antiretroviral therapy and 66% had a suppressed viral load at their most recent test — but only 62% were suppressed at every test in the previous 12 months.3 The distance between those last two numbers is the story of this page.

So if you are reading this because you have a gap, you are not an outlier who broke something. You are inside the most common experience in American HIV care. Numbers like these do not describe a country full of people making bad choices — they describe a delivery system that loses nearly half the people it has already diagnosed. It feels shameful because nobody talks about it, not because it is rare.

And the evidence on coming back is encouraging. A systematic review in PLOS Medicine found that programs designed to find and re-engage people lost to follow-up returned 39% of everyone on their lists to care, and 58% of the people actually found alive and out of care.10 Coming back is not a long shot. It is the expected outcome once someone reaches out.

The numbers: where the care continuum actually leaks

Public health describes HIV care as a "continuum" — steps from diagnosis to viral suppression. It is useful because it shows exactly where people fall out, and the drop-off is not evenly spread. Here is the national picture for 2024.1

Two things stand out. The U.S. system is good at diagnosis and initial linkage and weak at keeping people connected over years — which makes sense, because linkage is one event and retention is a permanent negotiation with money, transportation, housing, mental health, and time off work. And the groups at the bottom of every step are largely the same groups. That is structural, not coincidental.

What pushes people out: structural drivers first

When clinicians guess why someone stopped coming, they tend to guess motivation. When researchers ask people directly, the answers are overwhelmingly about money, distance, paperwork, and safety. The order below is deliberate: the structural layer comes first because it does the pushing, and the proximate causes further down are largely downstream of it.

The structural layer

HIV.gov names it without hedging: racism, discrimination, HIV stigma, and homophobia make it harder to seek and receive high-quality care, alongside poverty, lower educational attainment, transportation access, language barriers, mistrust of the health care system, and fear of disclosing immigration status. The same guidance lists changes in health care coverage and moving as common reasons care stops.2 These are conditions imposed on people, not choices made by them.

• Coverage loss. A coverage change is on HIV.gov's list of why care stops,2 and insufficient insurance was one of the barriers that distinguished people not retained in care from people who were.4 It is also among the most fixable items on this page \u2014 see insurance restart.
• Transportation. Expensive or unreliable transportation was among the barriers most strongly separating people not retained in care from those retained,4 and structural barriers like transportation accounted for 65% of the reasons among people who had moved their care elsewhere.5
• Housing and food. Twenty percent of people living with HIV in national surveillance experienced homelessness or unstable housing in the past year, and 20% experienced food insecurity.3 A 9 a.m. appointment across town is not a scheduling question when you are moving between couches. CDC's social determinants reporting tracks residential instability and cost-burdened households for exactly this reason.23
• Poverty and income. CDC's surveillance of social determinants finds the worst linkage and suppression outcomes concentrated in the counties with the highest poverty and lowest median income.23 Nationally, the lowest figures on every continuum step belong to the groups carrying the heaviest economic load.1
• Stigma, mistrust, and medical racism. HIV stigma was one of the barriers cited far more often by people not retained in care.4 Mistrust of the health care system is a rational response to how that system has treated people, not a personality trait \u2014 and HIV.gov lists it as a driver.2 See HIV shame and stigma.
• Criminalization and incarceration. Release from a facility is one of the sharpest drop-off points on the continuum, and federal guidance ties it to unstable housing, lack of insurance and medication, overdose risk, and lost social supports \u2014 systemic consequences of how the country handles incarceration.16 See re-entry.
• Immigration status. Fear of disclosing immigration status appears on HIV.gov's own list of what makes care harder to seek and receive.2 That fear is manufactured by policy, not by the person carrying it.
• Clinics built around institutional convenience. The facilitators that research identifies are the mirror image of the barriers: patient-friendly services \u2014 transportation assistance, co-located care, flexible scheduling, reminders \u2014 plus social support and positive provider relationships.4 Where those are absent, people are pushed out by design rather than by decision.

The proximate causes are downstream

Depression, substance use, moving, and simply feeling fine do show up in the research \u2014 but they arrive attached to the structural layer above, and treating them as personal failings gets the causation backwards.

Qualitative work in BMC Infectious Diseases makes the relationship visible. Researchers interviewed 51 people living with HIV \u2014 25 retained in care, 26 not \u2014 and identified 12 barriers and five facilitators. People who stayed in care named an average of three barriers; people who did not named five. Both groups described depression, feeling sick, and competing life demands at similar rates. What actually separated the two groups was structural: expensive or unreliable transportation, HIV stigma, and insufficient insurance.4 In other words, depression did not decide who stayed. Resources did.

A study in Clinical Infectious Diseases traced people who had vanished from one clinic. Among those found receiving HIV care elsewhere, structural barriers like transportation dominated (65%), with clinic-based barriers at 33% and psychosocial at 27%. Among those genuinely not in care anywhere, the ranking flipped: psychosocial 76%, structural 51%, clinic-based 15%.5

That flip is important, and it is not a story about weak individuals. Much of what gets recorded as "lost to follow-up" is a person who moved their care and never told the old clinic. The people genuinely out of care are more often carrying untreated depression, trauma, criminalized substance use, or deep isolation \u2014 conditions the system failed to treat. That is why re-engagement consisting only of a mailed letter tends to fail, and why the interventions that work send a human being.

• Untreated mental health conditions. Seventeen percent of people living with HIV in national surveillance had symptoms of depression, and among those who needed mental health services, 24% did not receive them.3 The unmet need is the system's, not the person's.
• Substance use left untreated. People whose HIV was attributed to injection drug use had the lowest figures at every measured step in 2024.1 HRSA's answer was to build an intervention integrating buprenorphine treatment into HIV primary care \u2014 a structural fix for a structural problem.12 See HIV and substance use.
• Nobody was assigned to keep track of you. Ten percent needed HIV case management and did not get it \u2014 roughly one in six of everyone who needed it.3 That is a staffing and funding gap.
• Feeling fine. Undetectable feels like nothing at all. Being on treatment and being off it feel identical for weeks, which is a property of the medication rather than a lapse in character \u2014 and it is why the next section matters.

What happens when you stop ART — the honest timeline

This section is factual, not a scare tactic. You deserve accurate information about your own body without moralizing, and it happens to be more urgent than most people expect.

Viral rebound: days to weeks, not months

Federal HIV treatment guidelines state that viral rebound typically occurs within days to weeks after antiretroviral therapy stops, and has been observed as early as three to six days. The guidelines name the consequences directly — viral rebound, immune decompensation, and clinical progression — which is why planned interruption is not recommended outside a clinical trial.6

A 2025 meta-analysis in Nature Communications pooled 24 studies and produced the clearest timeline available. Median time to a viral load above 50 copies/mL was 16 days (IQR 13–25); above 400 copies/mL, 21 days; above 10,000 copies/mL, 32 days. More than 75% of people rebounded within 21 days, and by day 84 only 4% were still suppressed.7

The practical translation is about two weeks — not "eventually." If you have been off medication for a month, assume your viral load is detectable, and assume the same for transmission risk, because undetectable-equals-untransmittable depends on sustained suppression, not a lab result from last year. In a mixed-status relationship that is a conversation to have early, and PrEP for a partner is a reasonable bridge while you re-suppress.

Immune decline, and why it does not fully reverse

Immune recovery is the part people underestimate. At the 26th International AIDS Conference in 2026, Prof. Graeme Meintjes of the University of Cape Town and Queen Mary University of London presented data showing CD4 counts dropped by roughly 200 cells in the four months after treatment stopped in the SMART trial, with poorer recovery after each subsequent restart. The same session reported that by 2025, 65% of people in South Africa starting or restarting treatment with a CD4 count under 200 were returning after an interruption rather than starting for the first time — and that entering or re-entering outpatient care with a CD4 under 200 carries roughly 12% mortality over the following year.9

Researcher Haroon Moolla presented Western Cape data on about 150,000 adults starting treatment between 2017 and 2024, defining interruption as no medication in hand for 28 days or more. Sixty percent interrupted at least once. Those periods made up roughly one-fifth of total follow-up time but accounted for more than half of all first tuberculosis episodes. Tuberculosis risk during an interruption was about 10 times higher for people with a baseline CD4 of 200 or above and 13.5 times higher below 200 — and even after resuming and re-suppressing, TB risk stayed 54% higher, with each additional month off treatment adding roughly 2%. Moolla's conclusion was that health workers need to stay vigilant for TB not only at re-engagement but through subsequent follow-up.9

Two caveats, stated plainly. These are South African data, from a health system and tuberculosis epidemiology that differ substantially from the U.S., so absolute risks do not transfer directly. And none of it argues for staying away — it argues for coming back sooner, and for telling whoever sees you how long the gap was so they can screen appropriately instead of guessing.

One specific situation: long-acting injectables

If you were on long-acting injectable cabotegravir and rilpivirine and missed doses, this is time-sensitive in a different way. Guidelines advise transitioning to an oral regimen within four weeks of the last injection when long-acting therapy is discontinued, because drug levels decline slowly and a long tail of sub-therapeutic drug invites resistance.6 Guidelines also advise integrase-inhibitor genotypic resistance testing after virologic failure on long-acting therapy regardless of how long ago the last injection was.8 Say the words "I was on injectables" on your first call.

The shame loop — and how it actually breaks

The mechanics are predictable enough to diagram. You miss an appointment for a real reason. Rescheduling requires a call you do not have the energy for. A second appointment passes. Now the gap is long enough to require explanation, and the anticipated explanation feels humiliating, so you avoid it — which lengthens the gap and raises the cost of the explanation. The loop runs on the belief that you will be judged when you walk back in.

The people who run HIV clinics say the opposite. HIV.gov acknowledges the fear directly, then answers it: providers are usually concerned when patients stop coming and are happy to see them return to care. The guidance goes on to recommend talking openly about the reasons, so those reasons can actually be addressed.2

That reframe matters. The gap is not a confession — it is clinical information. A provider who knows you were off treatment for fourteen months orders different labs, screens for different infections, and thinks harder about your regimen than one who assumes you were adherent. Telling the truth is data, not apology.

Writing in TheBody about losing access to his medication for seven days because of a clinic error, health reporter Juan Michael Porter II described how fast the internal narrative turns on itself even for someone with steady care, insurance, and a job.

Seven days — not seven months. If a week can do that to someone with every advantage, a year-long gap producing paralysis is not weakness. It is a proportionate response to a system that made re-entry feel expensive.

What breaks the loop is not willpower. A meta-analysis of 39 studies covering 42 re-engagement and retention interventions found that the strategies improving all three outcomes — re-engagement, retention, and viral suppression — were patient navigation, appointment help and alerts, psychosocial support, and transportation assistance or appointment accompaniment, with pooled odds ratios of 1.79, 2.01, and 2.50.10 In other words: another human being who makes the call with you, rides with you, or meets you at the door. See peer navigators below, and our page on HIV shame and stigma if that is the central obstacle.

Re-engagement pathways: the systems built to find you

Most people do not know this: there are federally funded programs whose entire job is to notice you are not in care and reach out. You are not required to find your own way back alone.

Data to Care

Data to Care is a strategy in which health departments use routinely collected HIV surveillance data — lab reports, care records, program databases — to identify people who appear not to be in care, confirm whether that is accurate, offer linkage, and monitor whether it worked. CDC describes the components as identification, investigation, linkage to HIV medical care, monitoring the continuum, prevention and support services, and a feedback loop.11

The outcomes are instructive in both directions. In preliminary longitudinal analyses of December 2022 data presented by CDC's HIV Surveillance Branch, fewer than 20% of people flagged as presumptively not in care turned out to actually be out of care — most were receiving care somewhere the data did not capture, or had moved. Among those confirmed out of care, about 30% were linked through health department intervention and another 13% returned on their own. Of those linked or re-linked, 81% got there within 30 days, 63% achieved viral suppression within six months, and 73% within a year.11

So if a health department contacts you, it usually means a database has an incomplete picture, and a five-minute conversation resolves it. And once someone is genuinely re-linked, suppression follows for most people within months.

HRSA's evidence-informed re-engagement interventions

HRSA's Ryan White program funded a body of work called Dissemination of Evidence-Informed Interventions, which turned four tested approaches into free implementation manuals. Two are re-engagement interventions specifically: Transitional Care Coordination, connecting jail health systems to community HIV care, and Peer Linkage and Re-engagement of Women of Color with HIV. The others integrate buprenorphine treatment for opioid use disorder into HIV primary care and provide enhanced patient navigation.12 If your local clinic says it has no re-engagement program, the manuals for building one are free and federally vetted — advocates use them.

The PLOS Medicine review quantified the payoff: re-engagement programs returned 39% (95% CI 31–47%) of all people characterized as lost to follow-up and 58% (95% CI 51–65%) of those found alive and out of care, a relative risk of 1.20 (95% CI 1.08–1.32) versus standard of care.10 A 20% improvement over doing nothing sounds modest in a journal. Applied to the roughly 44% of people living with diagnosed HIV who were not retained in 2024,1 it is enormous.

The first call back — what to say, and to whom

The first call is the hardest thing on this page, so here is the smallest possible version. You do not need to explain the gap on the phone. You need to say four things: that you are living with HIV, that you have been out of care, roughly how long, and that you want an appointment.

Who to call, in order of ease

1. Your previous provider's office. HIV.gov recommends starting here — they will likely be glad to hear from you and will set up a re-engagement appointment.2 Your chart, labs, and treatment history are already there, which saves weeks.
2. A local HIV/AIDS service organization. HIV.gov notes these organizations have extensive experience helping people who left HIV care and want to return, and that many have peer navigators or linkage-to-care coordinators.2 If calling a clinic is too much, call one of these and let them make the clinical call with you.
3. The HIV.gov Testing Sites & Care Services Locator. Searchable by ZIP code, city and state, or coordinates; it returns Ryan White clinics, health centers, housing providers, mental health and substance use services, and other HIV service providers with addresses and phone numbers.2
4. The HRSA Contact Center at 1-877-464-4772 (TTY 1-877-897-9910), Monday–Friday 8 a.m.–8 p.m. Eastern, excluding federal holidays — useful when you cannot identify the Ryan White recipient in your area.15

A script you can read off the screen

"Hi. I'm living with HIV and I've been out of care for about [length of time]. I stopped taking my medication [when]. I'd like to get back into care — can you tell me what I need to do to get an appointment?"

That is the whole thing. If they ask why you stopped, "life got complicated" is a complete answer. If you want to say more, HIV.gov's guidance encourages it — discussing the reasons openly lets your provider help you address them so they do not recur.2 But that is an offer, not a requirement.

Worth mentioning on that first call

• How long you have been off medication — this drives resistance testing and lab ordering.8
• What regimen you were on last, especially if it was a long-acting injectable.6
• Whether you have insurance right now. If the answer is no or "I don't know," ask for a benefits counselor in the same call — Ryan White programs employ people for exactly this.15
• Any symptoms. Fever, night sweats, weight loss, a cough that will not clear, thrush, or shortness of breath change the urgency, and after a long interruption tuberculosis screening deserves specific attention.9
• What you need to physically get there. Bus passes, rideshare vouchers, and appointment accompaniment are real services with measured effect on retention.10

Our find care page covers locating a clinic in more detail, and HIV navigators covers who can make these calls alongside you.

Insurance restart: Ryan White, ADAP, Marketplace, Medicaid

Coverage loss is one of the most common reasons people fall out of HIV care and one of the most solvable. There are four doors, and they are not mutually exclusive.

Door 1 — Ryan White as the bridge

Ryan White is designed to be the bridge, not the destination. Federal guidance frames it as the payer of last resort, with eligibility resting on documented HIV diagnosis, low income as defined by the local recipient, and residency.15 It can cover your visits and medications while a Marketplace or Medicaid application is pending. You do not have to wait for coverage to be resolved before being seen.

Door 2 — AIDS Drug Assistance Program re-enrollment

Every state runs an AIDS Drug Assistance Program under Ryan White Part B, and re-enrollment after a lapse is routine administration, not a review of your behavior. Florida illustrates how it works: the state health department administers it as the Part B recipient, direct-dispense coverage serves people at 0%–100% of the federal poverty level with limited or no other coverage, Marketplace premium assistance runs from 75% to 400% of the federal poverty level, and the program also covers Medicare Part C and D premiums, deductibles, copayments, and coinsurance. Since a 2022 pharmacy benefit manager change built on a 340B network, the program is designed to get enrolled direct-dispense clients formulary medications within 24 hours, with eligibility files transmitted several times daily so newly enrolled clients can access services the same day.20 Same-day or next-day medication access is an achievable ask. Our ADAP changes page tracks program shifts.

Door 3 — Marketplace special enrollment

You do not have to wait for Open Enrollment if a qualifying life event happened. HealthCare.gov allows a Special Enrollment Period generally for 60 days following (or, for some events, before) a qualifying event such as losing coverage, moving, marriage, or a birth or adoption. If you lost Medicaid or CHIP, the window is 90 days. After choosing a plan you may need to submit documents confirming the event, generally within 30 days. Open Enrollment itself runs November 1 through January 15 in most states.17

Door 4 — Medicaid redetermination

Losing Medicaid at renewal is often paperwork, not ineligibility — an unreceived letter, an address change, a missed deadline. Because losing Medicaid or CHIP triggers a 90-day Marketplace Special Enrollment Period,17 a termination is a door opening as well as one closing. Ask a Ryan White benefits counselor to work both tracks at once.

Resistance testing before you restart

This is the most technical section here, and the one that can most change the next decade of your treatment. Read it before your first appointment so you can ask for what you need.

When you take antiretroviral therapy, drug pressure selects for resistant virus — mutations that survive the medication. When you stop, that pressure disappears and wild-type virus re-emerges as the predominant population in your plasma. Federal guidelines note this reversion can occur within the first four to six weeks after stopping, and that standard genotypic assays generally cannot detect variants making up less than 10%–20% of the viral population.8

Two consequences follow, pulling in different directions. First, testing works best while you are still on treatment or right after — guidelines recommend testing while taking a regimen or within four weeks of discontinuing non-long-acting antiretrovirals; after that, testing may still help, but previously selected mutations can be missed because the drug pressure is gone.8 Second, a reassuring-looking test after a long gap does not mean the resistance is gone. Guidelines warn that reinitiating the same drugs after plasma reversion often leads to early virologic failure, because resistant virus is archived in cells and re-emerges under renewed drug pressure, and that all prior and current resistance results should be reviewed when constructing a new regimen.8

Carry that second point into the exam room: your resistance history does not expire. If you had a resistance test years ago at another clinic, retrieving those records is one of the highest-value things you can do for your own care.

When testing is and is not recommended

• Testing is recommended when HIV RNA is above 1,000 copies/mL and at 501–1,000 copies/mL; it may be considered for confirmed levels of 201–500, and is not recommended at or below 200 copies/mL because assays cannot amplify enough virus.8
• Below 1,000 copies/mL or undetectable, a proviral DNA next-generation sequencing assay may add information — but guidelines advise interpreting it cautiously and combining results into a cumulative genotype rather than treating it as definitive.8
• If treatment will be deferred rather than started immediately, repeat testing may be considered when therapy actually begins.8
• After virologic failure on long-acting cabotegravir and rilpivirine, integrase-inhibitor genotyping is advised regardless of time since the last injection.8

Practically, restarting after a long gap often means a new regimen rather than your old one — frequently a modern single-tablet or integrase-inhibitor-based combination with a higher barrier to resistance. That is not a demotion. Options in 2026 are dramatically better than in 2016, and many people who struggled with an older regimen do fine on a current one. Our understanding your labs page explains the numbers you will see on the way back.

Peer navigators: the intervention with the best track record

A peer navigator is a person living with HIV, or someone with closely shared experience, trained and paid to help others get and stay connected to care. HIV.gov describes them as individuals from the community trained to guide people through the medical and social services they need, noting many are living with HIV themselves and have learned how to make it easier to take medication and remain in care.2

Ask directly: "Does this clinic have a peer navigator, linkage-to-care coordinator, or community health worker I can work with?" If not, ask a local AIDS service organization — HIV.gov identifies those organizations as where peer navigators and linkage coordinators are commonly based, and the HIV.gov locator surfaces both clinics and other HIV service providers by ZIP code.2

These roles are also professionalizing, which matters for sustainable funding and fair pay. The Nationally Certified Community Health Worker credential involves 12 days of instruction across 11 core competencies plus 160 hours of field experience, and national certification does not replace state or Medicaid-specific certification where those exist.14 If you are a person living with HIV who has been through a gap and come back, that experience is a professional qualification in this field — not something to hide.

Re-entry from incarceration — the highest-risk transition

Release from jail or prison is one of the sharpest drop-off points on the entire continuum. Care inside a facility is often consistent — fixed schedule, observed doses, no transportation problem. Then the door opens and every one of those supports disappears at once.

HRSA's account of why Transitional Care Coordination was developed names the risks precisely: without transition assistance, people released from jail face unstable housing, lack of insurance and medication, overdose after a period of detoxification, exacerbation of mental health conditions, and loss of social supports. The intervention's design is to connect jail health systems to community HIV care before release rather than after. Ryan White funds are explicitly available for this work: HRSA policy guidance allows funds to support transitional services for people in federal and state prisons and short-term or transitional services for people in local jails or under community supervision.16 If a case manager says Ryan White cannot help with a re-entry plan, that guidance is the document to point to.

What to line up before the door opens

• Medication in hand at release, not a prescription to fill later. In Florida's 2019 HIV Care Needs Survey, among respondents incarcerated in the prior 12 months, only 29.4% received a supply of HIV medication at release, 24.2% got a referral to medical care, and 22.3% a referral to case management — while 40.3% received no HIV-related information or assistance at all.20
• An appointment with a date on it. Florida's Pre-Release Planning Program provided linkage services to 644 people in 2021 and linked 305 to care; 160 — 52% of those linked — kept the appointment, with recidivism, housing, and transportation the recurring barriers.20
• Coverage restarted. Medicaid is frequently suspended or terminated during incarceration. Ask a discharge planner or Ryan White eligibility worker to begin reinstatement before release, and remember Ryan White can bridge the gap while it processes.15
• Follow-up that persists. Florida's Jail Linkage Program, operating through 14 county health departments, provides testing, education, linkage to care and support services after release, and follow-up for up to three months.20

Our HIV re-entry page is the practical companion here, and HIV and incarceration covers care inside.

Who falls out most — and why it is structural

The disparities in retention are not mysterious. They track money, housing, safety, discrimination, and whether the nearest clinic treats you decently.

Transgender women. A PLOS Medicine analysis of Ryan White program data found that in 2016, among 6,534 transgender women served, 79.8% were retained and 79.0% virally suppressed — compared with 83.7% and 84.0% among 143,173 cisgender women and 81.0% and 85.9% among 382,591 cisgender men. The disparity was sharpest for Black transgender women, less likely to be retained than Black cisgender women (adjusted prevalence ratio 0.95) and substantially less likely to be virally suppressed than either Black cisgender women or Black cisgender men (aPR 0.55).19 See HIV and trans women.

Women overall, and Black women specifically. In 2024 surveillance, women had lower receipt of care (76.6%), lower viral suppression (67.8% against 68.5% nationally), and lower linkage within a month (82.2%).1 CDC has also reported viral suppression lowest among Black people (61%) and women (64%), and that in 2022, 47% of estimated new HIV infections among women were among Black women.19 Highest incidence with lowest suppression is a system failure, not a behavior pattern. See HIV and women.

People who use drugs. People whose HIV was attributed to injection drug use had the lowest figures on every step measured in 2024: 80.2% linkage, 66.3% receipt of care, and 57.2% viral suppression — more than eleven points below the national rate.1 HRSA's decision to build an intervention around integrating buprenorphine treatment into HIV primary care reflects a straightforward insight: treating both in one place removes a whole category of drop-off.12 See HIV and substance use.

Young people, older adults, and people without stable housing. People aged 13–24 had the lowest linkage of any age group at 82.0%, while people 65 and older had the lowest receipt of care (71.5%) and among the lowest suppression (65.8%) — drop-out is not only a young person's phenomenon.1 Housing sits underneath all of it: 20% of people living with HIV in national surveillance experienced homelessness or unstable housing in the past year.3 Florida's planning data found the highest out-of-care rates — above 21% against a statewide 20% — among people experiencing homelessness, non-White minorities, people born outside the U.S., and people who inject drugs.20 See HIV and housing.

Technology tools that actually have evidence

Most "HIV app" claims are marketing. A few tools have real randomized or longitudinal evidence, and the strongest is almost comically simple: a weekly text message from a human being.

Purpose-built platforms point the same direction. PositiveLinks, a smartphone platform combining appointment reminders, medication check-ins, mood tracking, community messaging, and direct provider contact, was studied in 127 participants: engagement in care and viral suppression improved significantly at six months and were sustained at 24 months, and high users were 2.09 times more likely to achieve viral suppression than lower users.18

Telehealth deserves specific mention because it removes several of the strongest predictors of falling out: transportation, time off work, and physically walking into an HIV clinic. Florida began offering HIV telehealth through its county health department system in January 2018 and by May 2021 was averaging more than 100 telehealth services per month, available across all 67 county health departments and including same-day or rapid antiretroviral therapy.20 Our HIV telehealth page covers what a virtual visit can and cannot handle.

And the low-tech version is fine. The most common reason people gave for missing their last dose in national surveillance was forgetting (68%), with a change in routine or travel second (43%).3 Those are logistics problems with logistics solutions: a phone alarm, a pillbox, tying the dose to something you already do daily, pharmacy refill texts, mail delivery, or asking about a long-acting injectable if daily pills are the obstacle.10

Florida: Data to Care, Test and Treat, and where to call

Florida is instructive on this topic because it has run re-engagement infrastructure longer than most states and publishes its results.

At the end of 2021, an estimated 120,502 people were living with HIV in Florida. Of those, 80% (95,959) received at least one documented viral load, CD4 result, medical visit, or HIV-related prescription during the year; 73% (88,274) were retained in care; and 69% (83,556) were virally suppressed. Twenty percent — 24,543 people — received no HIV-related care at all. Among people retained in care, 90% were virally suppressed.20 That last figure is this article's argument in one line: staying connected is what produces suppression.

Florida has run a statewide Data to Care program since 2015, using surveillance data to generate lists of people not in care, offer linkage services, and connect them to care — targeting people not linked within a month of diagnosis and people who are not virally suppressed and are part of an identified transmission cluster, with expanding focus on people experiencing homelessness, non-White minorities, people born outside the U.S., and people who inject drugs.20 If a Florida county health department contacts you about HIV care, that is what is happening — an offer, not an enforcement action.

Test and Treat: the red-carpet door for people returning

Since 2016 Florida has operated a rapid-access antiretroviral therapy program called Test and Treat, and it serves both people newly diagnosed and people previously diagnosed who have been out of care and are returning. It provides expedited provider visits, expedited labs, antiretroviral therapy, and retention-in-care specialists — described as a "red-carpet" process with immediate access to a provider who can start medication right away.20

The enrollment numbers show how well-worn this path is: of more than 7,374 clients enrolled statewide since inception, 3,342 were newly diagnosed and 4,032 were previously diagnosed people returning to care — more returners than newcomers. Average time to treatment initiation was 5.6 days for Test and Treat enrollees versus 38.3 days for those not enrolled, and average time to viral suppression 92.2 days versus 146.4 days.20 Ask for Test and Treat by name.

Where to call in Florida

Florida's HIV services run through 67 county health departments organized into 14 HIV partnership areas, each with an HIV/AIDS Program Coordinator, with Ryan White Part B funds allocated annually to 14 lead agencies.20 The Florida Department of Health's HIV/AIDS Section describes patient care programs covering health care, dental care, transportation, case management, housing assistance, and medications, and publishes direct lines including 800-933-3413 for general clinical questions, 888-448-4911 for post-exposure prophylaxis, and 888-448-8765 for perinatal HIV questions, with U=U materials in English, Spanish, and Haitian Creole.21

One local note from where this site is written. Among Florida's seven Ending the HIV Epidemic counties — which together held 72% of the state's diagnosed population — Pinellas had the highest viral suppression rate at year-end 2021 at 77%, against a statewide 69% and a low of 63% in Miami-Dade.20 Where you live inside this state changes your odds. If you are in a lower-performing county, that is a reason to be more insistent about navigation and transportation support, not less.

Do this today

Everything above supports one action, and it does not require a plan, a good day, or a resolved insurance situation.

1. Make one phone call. Your old clinic first — HIV.gov's guidance is that they will likely be glad to hear from you and will set up a re-engagement appointment.2 If that number is gone, use the HIV.gov Testing Sites & Care Services Locator to find Ryan White clinics and HIV service providers by ZIP code,2 or call the HRSA Contact Center at 1-877-464-4772 (TTY 1-877-897-9910), Monday–Friday 8 a.m.–8 p.m. Eastern.15 In Florida, 800-933-3413 reaches the state's general clinical line.21
2. Say the four sentences. "I'm living with HIV. I've been out of care for about [length]. I stopped my medication [when]. I'd like an appointment." That is sufficient — no explanation of the gap is required.2
3. Ask for three things by name — a peer navigator or linkage-to-care coordinator,2 a benefits worker for Ryan White and ADAP,15 and transportation help if you need it.10
4. Ask about resistance testing before you restart, especially after a long gap, and say so if you were on a long-acting injectable.8
5. Mention any symptoms, particularly fever, night sweats, unexplained weight loss, or a persistent cough — tuberculosis risk stays elevated during and after an interruption, and it is worth screening for rather than assuming.9
6. Put the next appointment in your phone before you hang up, with a reminder two days out. Appointment alerts are among the interventions with measured effect on retention.10